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ET B –/– mice.  Conclusions: The potential protective effects of 
endothelial ET B are important in limiting pulmonary vascu-
lar muscularisation and the development of pulmonary arte-
rial hypertension in response to hypoxia. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Pulmonary arterial hypertension (PAH) is a progres-
sive condition involving small pulmonary arteries (PAs) 
characterised by a sustained increase in pulmonary vas-
cular resistance and vascular remodelling leading ulti-
mately to right ventricular failure and premature death 
 [1] . Several lines of evidence implicate endothelin-1 (ET-
1) in the aetiology and progression of PAH. First, ET-1 is 
a potent vasoconstrictor and mitogen  [2] . Second, plasma 
concentration of ET-1 correlates with severity of PAH in 
animal models  [3–5] and patients  [6] , and third, non-se-
lective and selective endothelin A receptor antagonists 
improve symptoms and slow the progression of PAH  [7, 
8] . The lung is an important site of ET-1 production with 
a concentration of ET-1 five times greater than that seen 
in other organs  [9] . Endothelin B receptor (ET B ) mRNA 
is expressed abundantly in the lung  [10] , particularly in 
distal segments of the pulmonary vascular tree  [11] , where 
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 Abstract 
 Background: We hypothesised that the potential protective 
effects of endothelial ET B are important in limiting pulmo-
nary vascular muscularisation, vasoconstriction and the de-
velopment of pulmonary arterial hypertension in response 
to hypoxia.  Methods: EC-specific ET B knockout mice (EC
ET B –/– ) and control mice (ET B f/f ) were subjected to hypobaric 
hypoxic (10% FiO 2 ) or normoxic conditions for 14 days before 
assessment of right ventricular pressure and pulmonary vas-
cular morphology and function.  Results: During normoxia, 
no difference in right ventricular pressure was detected be-
tween EC ET B –/– (23.7  8 1.7 mm Hg) and ET B f/f mice (20.2  8 
1.5 mm Hg). Hypoxia induced an exaggerated increase in 
right ventricular pressure in EC ET B –/– mice (34.4  8 1.2 mm 
Hg vs. 24.6  8 1.4 mm Hg), accompanied by an increase in 
right ventricular mass. No effect was observed in ET B f/f mice. 
Endothelin-1 constricted pulmonary arteries from both 
groups, although maximum response was similar irrespec-
tive of inspired oxygen or genotype. Hypoxia increased the 
percentage of muscularised vessels in both groups of mice, 
but the percentage increase was significantly greater in EC 
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it is found in the endothelium and media of pulmonary 
blood vessels as well as in bronchioles and alveoli.
 In contrast, endothelin A receptors (ET A ) are localised 
to the media of large proximal PAs and veins with rela-
tively little expression in distal arterioles  [11–13] . Hypox-
ia increases the expression of ET-1, ET A and ET B through-
out the rat lung  [10, 12] with histological evidence to sug-
gest a preferential increase in endothelial cell (EC) ET B 
expression in distal segments  [13] . EC ET B elicit vasodi-
latation and anti-mitogenic effects through the release of 
nitric oxide (NO) and/or prostaglandin I 2 (PGI 2 )  [14, 15] . 
Increased ET-1/EC ET B -mediated vasodilatation has thus 
been hypothesised to protect against hypoxia-induced 
vasoconstriction  [13] , and studies in rats suggest that ET B 
deficiency exacerbates monocrotaline-  [16] and hypoxia-
induced PAH  [17] . Pulmonary ET B also clear ET-1 from 
the plasma  [18] , further limiting ET A -mediated vasocon-
strictor and mitogenic effects. 
 Vascular smooth muscle cell (VSMC) ET B mediate va-
soconstriction in humans  [19] . In hypoxic rat models  [20] 
and sheep models of embolism-induced PAH and PAH 
secondary to aortopulmonary shunting, there is evidence 
of increased VSMC ET B -mediated vasoconstriction  [21, 
22] . Activation of ET A and ET B on VSMC by ET-1 also 
promotes cellular hypertrophy  [11] and hence may pro-
mote the progression of PAH through muscularisation of 
small pulmonary arterioles. Thus, with respect to the de-
velopment of PAH, pulmonary ET B have the potential to 
elicit both protective and detrimental effects. Study of the 
interplay between EC and VSMC ET B is likely to increase 
our mechanistic understanding of the role of the endo-
thelin system in the pathogenesis of PAH. We have previ-
ously generated EC-specific ET B knockout (KO) mice 
that exhibit endothelial dysfunction in the absence of sys-
temic hypertension, with evidence of impaired endoge-
nous NO release and increased plasma ET-1  [23] . Other-
wise, they have normal feeding and growth rates, exhibit 
normal behaviour and are healthy. Here we have used this 
model to determine whether the potential protective ef-
fects of EC ET B are important in limiting pulmonary vas-
cular muscularisation and the development of PAH dur-
ing hypoxia.
 Methods 
 Experimental Animals  
 Mice featuring selective KO of EC ET B were generated using a 
Cre- LoxP approach as previously described  [23] . Briefly, mice 
with  loxP sites flanking exons 3 and 4 of the ET B gene (‘floxed’ 
mice, ET B f/f ) were crossed with mice expressing a Cre recombi-
nase transgene in an EC-restricted pattern (WW/Tie2-Cre)  [24] 
to produce EC-specific ET B KO mice (EC ET B –/– ). Genotyping to 
identify the flox and recombined alleles was performed by South-
ern blot and by PCR using primers amplifying a sequence span-
ning the 3  and 5   loxP sites (forward primer: TCA GTT GTA 
ATG AGA CAC AGA C; reverse primer: AGC CAT AAA GTC 
ACA GCC ATT C). The Tie2-Cre transgene was detected by PCR 
as described  [24] . Male mice aged 8–12 weeks (weight 25–35 g) 
were studied and EC ET B –/– mice compared with ET B f/f control 
mice in all experiments. The genetic background of each group 
was 129/Ola; BKW; C57Bl/6; SJLF 1 . All procedures were carried 
out with the approval of the University of Glasgow and Univer-
sity of Edinburgh Local Ethical Review Committees, under Home 
Office Project and Personal Licence authority.
 Hypobaric Chambers 
 EC ET B –/– mice and control mice (10 animals/group) were ex-
posed to hypobaric hypoxic conditions for 14 days by housing 
them in a specially designed hypobaric chamber, as previously 
described  [20] . The chamber was depressurised over the course of 
2 days to 550 mbar [55 kPa or 413 mm Hg, equivalent to FiO 2 (per-
centage oxygen in inspired air) = 10%]. A further 10 age-matched 
mice of each genotype were maintained in the same room breath-
ing air at atmospheric pressure (FiO 2 = 21%). All mice were al-
lowed free access to standard rodent chow and water throughout 
the study and kept under 12-hour light/dark cycles.
 Haemodynamic Studies 
 Anaesthesia was induced with 2–4% halothane and main-
tained with 1.5% halothane using a mix (1 part:3 parts) of NO 2 
and high-flow O 2 . Pressure and heart rate measurements were 
performed and analysed as previously described  [25] . Systemic 
arterial pressure was measured via a cannula (Portex, 0.75 mm 
OD) inserted into the right carotid artery. A 25-gauge needle was 
advanced into the right ventricle (RV) via a transdiaphragmatic 
approach for measurement of right ventricular pressure (RVP). At 
the end of the experiment, mice were killed by lethal overdose of 
halothane. The heart was removed, blotted dry of blood and 
weighed. The right lung was placed in formal saline (1 part 37% 
formaline:9 parts 0.9% saline) for histology and third-order PAs 
dissected from the left lung for wire myography experiments. 
 Assessment of RV Hypertrophy 
 Hearts were dissected clean of pericardial tissue, blotted dry 
and the atria and great vessels removed to the plane of the atrio-
ventricular valves. The RV free wall was dissected free from the 
left ventricle and septum (LV+S) and weighed. The ratios of RV/
body weight (BW), RV/(LV+S) and RV/total ventricles (TV) were 
calculated  [25] .
 Lung Histology 
 The right lung was embedded in paraffin and 10-  m sections 
stained with Miller’s elastin stain  [26] and with picrosirius red for 
collagen  [27] . Sections were microscopically assessed for muscu-
larisation of small PAs (25–100   m external diameter) associated 
with an airway distal to the respiratory bronchiole. Arteries were 
considered muscularised if they possessed a distinct double-elas-
tic lamina visible for at least half the diameter of the vessel in 
cross-section ( fig. 2 ). The percentage of vessels containing dou-
ble-elastic lamina was calculated as the number of muscularised 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f E
di
nb
ur
gh
   
   
   
   
   
   
   
   
   
   
  
12
9.
21
5.
14
9.
96
 - 
6/
10
/2
01
3 
12
:1
0:
15
 P
M
 Kelland et al. 
 
J Vasc Res 2010;47:16–22 18
vessels/total number of vessels counted per section  ! 100. Three 
sections from each right lung were assessed for every mouse. A 
total of 6 mice per group were analysed.
 In vitro Wire Myography 
 Third-order PAs (first interlobar; approx. 300   m internal 
diameter) from the left lung were cut to yield two 2 mm-long 
segments, which were then mounted onto a wire myograph. Ves-
sels were bathed in Krebs buffer solution (118.4 m M NaCl; 25 m M 
NaHCO 3 ; 4.7 m M KCl; 1.2 m M KH 2 PO 4 ; 0.6 m M MgSO 4 ; 2.5 m M 
CaCl 2 ; 11 m M glucose; pH 7.4) at 37 ° C and constantly bubbled 
with 16% O 2 /5% CO 2 . Tension was applied to give transmural 
pressures equivalent to 12–14 mm Hg for controls and 30–33 
mm Hg for hypoxic animals. These pressures are similar to 
those experienced by pulmonary vessels in vivo in rodents un-
der similar hypobaric conditions  [28, 29] . Following equilibra-
tion, PA rings were constricted twice with 50 m M KCl solution. 
Cumulative concentration-response curves were constructed 
for ET-1 (10 –15 to 10 –7  M ) following a 30-min incubation with
100   M N-nitro- L -arginine methylester ( L -NAME) or vehicle. 
All responses were expressed as a percentage of the maximal 
KCl-induced constriction. 
 Drugs 
 Halothane, formalin and  L -NAME were all purchased from 
Sigma-Aldrich (Gillingham, UK). ET-1 was purchased from 
 Merck Chemicals Limited (Nottingham, UK).
 Data Analysis and Statistical Procedures 
 Data are expressed as means  8 SEM. Statistical comparisons 
were made by two-way ANOVA. When significance was attained 
(p  !  0.05), differences were established using the Bonferroni mul-
tiple comparison test. In the myography studies, pEC 50 values 
were calculated from concentration-response curves by graphical 
interpolation (GraphPad Prism 4.0). 
 Results 
 Haemodynamic Studies 
 Systemic mean arterial blood pressure was not signif-
icantly different between EC ET B –/– mice and controls 
under either normoxic (ET B f/f 99  8 4 mm Hg; EC ET B –/– 
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 Fig. 1.  a Systolic right ventricular pressure of anaesthetised
ET B f/f and EC ET B –/– mice (n = 10).  b Percentage of muscularised 
vessels in lungs from EC ET B –/– mice and ET B f/f controls (n = 6) 
following 14 days of normoxia or hypobaric hypoxia.  c Right ven-
tricular hypertrophy, as determined by the ratio RV/(LV+S), of 
ET B f/f and EC ET B –/– mice (n = 10). 
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101  8 4 mm Hg) or hypoxic conditions (ET B f/f 93  8 
4 mm Hg; EC ET B –/– 103  8 4 mm Hg), as previously re-
ported  [23] . No difference in heart rate was observed. Al-
though systolic RVP was similar between genotypes un-
der normoxic conditions, following 2 weeks of hypoxia, 
systolic RVP in EC ET B –/– mice was significantly elevated 
compared to hypoxic ET B f/f controls ( fig. 1 a).
 Right Ventricular Hypertrophy 
 Relative right ventricular mass, as measured by RV/
(LV+S) and RV/TV ratios, tended to be lower in normox-
ic EC ET B –/– mice compared to normoxic ET B f/f controls. 
Body weight fell by approximately 3.4 g in both genotypes 
following 2 weeks of hypoxia. Both genotypes demon-
strated a significant increase in RV/BW ratio when ex-
posed to hypoxia. However, only hypoxic EC ET B –/– mice 
demonstrated a significant increase in RV/(LV+S) ratio 
and RV/TV, suggesting a preferential increase in RV mass 
( fig. 1 c;  table 1 ). 
 Vascular Morphology 
 Under normoxic conditions, the percentage of muscu-
larised vessels was similar in EC ET B –/– and ET B f/f mice. 
Following hypoxia, muscularisation was observed in a 
significantly greater proportion of vessels from EC
ET B –/– mice compared to controls ( fig. 1 b, 2 ).
 Myography 
 Neither genotype nor FiO 2 influenced the E max or 
pEC 50 of PAs to ET-1 ( table 1 ). Treatment with  L -NAME 
did not significantly alter the maximum constriction or 
tissue sensitivity to ET-1 in either genotype ( table 2 ). 
Table 1. Indices of right ventricular hypertrophy in ETBf/f and EC ETB–/– mice under normoxic conditions or 
following 14 days of hypobaric hypoxia
ETBf/f EC ETB–/–
RV/(LV+S) RV/TV RV/BW RV/(LV+S) RV/TV RV/BW
Normoxic 0.2580.009 0.2080.006 0.8080.065 0.2280.009 0.1880.006 0.7580.047
Hypoxic 0.2880.012 0.2280.007 1.0380.083* 0.2980.017* 0.2280.010* 0.9880.045*
Values are means 8 SEM (10 animals/group). * p < 0.05 for comparison between normoxic and hypoxic 
animals within each genotype.
Normoxic Hypoxic
10 μm
a b
 Fig. 2. Representative sections illustrating normal murine small PAs under normoxic conditions ( a ) and mus-
cularised arteries with a double elastic lamina ( b , arrow) that develop following 14 days of hypobaric hypoxia. 
The proportion of muscularised to normal vessels in response to hypoxia was greater in EC ET B –/– mice than 
in ET B f/f mice. Sections are stained with Miller’s elastin stain and picrosirius red collagen stain. 
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 Discussion 
 This study demonstrates that in response to 14 days of 
hypobaric hypoxia, selective loss of EC ET B results in an 
exaggerated increase in systolic RVP, an increase in RV 
mass and an increase in the proportion of muscularised 
small PAs. However, we did not observe systemic hyper-
tension, implying a selective effect of loss of EC ET B in 
the pulmonary vasculature. 
 After 14 days of hypoxia, we observed no increase
in systolic RVP in control ET B f/f mice that were of the
same genetic background as EC ET B –/– mice. The devel-
opment of hypoxia-induced PAH differs between mice 
of different strains, although even relatively resistant 
mice have been shown to develop raised systolic RVP 
after 4 weeks of hypoxia  [30] . It is likely that our control 
ET B f/f mice would have developed elevated systolic RVP 
after such a prolonged period of hypoxic exposure. 
However, we can conclude that loss of EC ET B either ac-
celerated the increase in systolic RVP in this strain or 
enabled PAH to develop in a strain resistant to the ef-
fects of hypoxia. 
 There are several possible mechanisms that may un-
derlie the exaggerated increase in RVP in EC ET B –/– mice. 
First, EC ET B vasodilator pathways are likely to be an im-
portant protective mechanism that limits the develop-
ment of PAH during chronic hypoxia. In vitro studies of 
rat pulmonary microvascular ECs demonstrate that an 
increase in shear stress increases ET B expression and en-
hances ET-1-mediated ET B -dependent eNOS activation 
 [31] . Lungs from rescued ET B -deficient rats also demon-
strate an exaggerated pressor response to ET-1  [32] , due 
in part to reduced NO and PGI 2  production  [17] . Studies 
of eNOS over-expressing  [33] and eNOS KO mice  [34, 35] 
have revealed that a reduction in EC-derived NO increas-
es vascular tone and muscularisation of PAs. We have 
previously reported endothelial dysfunction with de-
creased NO bioavailability in the absence of systemic hy-
pertension in the aortae of EC ET B –/– mice  [23] . Thus, 
impaired EC ET B -mediated NO/PGI 2 release from pul-
monary resistance vessels during hypoxia may have con-
tributed to the development of PAH. We also observed an 
exaggerated increase in the number of muscularised 
small pulmonary vessels in EC ET B –/– mice following hy-
poxia. Thus, loss of ET B -mediated NO release may also 
have had a permissive effect on hypoxia-induced vessel 
muscularisation. 
 Second, EC ET B –/– mice have elevated plasma ET-1 
concentration  [23] that may directly exert pressor and 
mitogenic actions to further promote the development of 
PAH. Studies in our laboratory demonstrate that clear-
ance of ET-1 is impaired and plasma ET-1 increased ap-
proximately 4-fold in these mice  [23] . Increased plasma 
ET-1 has also been reported in patients with PAH  [6, 36, 
37] , though this may reflect increased production rather 
than impaired pulmonary clearance  [38] . Loss of ET B sig-
nalling has also been reported to increase ECE-1 mRNA 
expression  [39] , which may further contribute to an in-
crease in ET-1. However, the limited experimental evi-
dence available suggests that an isolated increase in ET-1 
is insufficient to cause PAH. Under normoxic conditions, 
rats chronically infused with ET-1 by subcutaneous pump 
do not develop raised systolic RVP  [40] . Similarly, trans-
genic mice that over-express preproET-1 have elevated 
plasma ET-1, exhibit pulmonary inflammation and fi-
brosis, but do not develop PAH, even when exposed to 
mild hypoxia (FiO 2 16%)  [41] . Thus, although an increase 
in ET-1 may contribute to many of the pathological pro-
cesses associated with PAH, concomitant loss of NO/
PGI 2 -mediated vasodilator pathways is likely to be neces-
sary for PAH to develop. 
Table 2. Potency and maximum effect of ET-1 in PA rings from EC ETB–/– and ETBf/f mice
ETBf/f EC ETB–/–
pEC50 Emax n pEC50 Emax n
Normoxic 9.280.1 121.984.8 7 8.880.1 109.787.2 7
Hypoxic 10.180.2 116.889.0 5 9.680.1 125.485.5 5
Normoxic + L-NAME 9.780.2 126.383.4 7 9.180.9 120.285.0 6
Hypoxic + L-NAME 10.180.2 124.387.1 6 10.580.1 143.086.0 9
Emax is expressed as a percentage of the maximal contractile response to 50 mM KCl solution.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f E
di
nb
ur
gh
   
   
   
   
   
   
   
   
   
   
  
12
9.
21
5.
14
9.
96
 - 
6/
10
/2
01
3 
12
:1
0:
15
 P
M
 ET B in Pulmonary Hypertension J Vasc Res 2010;47:16–22 21
 Although expression of Tie2 was thought to be ex-
clusively restricted to ECs, Tie2-positive monocytes have 
now been identified  [42, 43] . Thus, Cre-Lox- mediated 
ablation of the ET B gene may have occurred in such in-
flammatory cells, as well as in ECs, potentially compli-
cating the interpretation of the phenotype of the EC
ET B –/– mice. Although no inflammatory infiltrate was 
seen in the lung sections from the hypoxic EC ET B –/– 
mice, further studies to clarify the role of such macro-
phages in the development of PAH are  required. 
 We found no difference in the maximal response or 
sensitivity of 3rd order PAs to ET-1 in EC ET B –/– mice. 
The absence of any change in ET-1-mediated constriction 
following  L -NAME suggests that NO does not contribute 
significantly to vascular tone in vessels of this size. This 
finding does not necessarily contradict our hypothesis 
that loss of ET B -mediated NO release contributed to hy-
poxia-induced PAH in EC ET B –/– mice. Indeed, studies of 
rat intrapulmonary arteries following 4 h of either nor-
moxia or hypoxia found similar results, demonstrating 
no effect of nitro- L -arginine on ET B -mediated contrac-
tion  [44] . In contrast, chronic in vivo telemetric measure-
ments of PAP demonstrate that  L -NAME acutely increas-
es PAP in the mouse  [45] , suggesting that NO is an im-
portant determinant of PAP in this species. Thus, 
hypoxia-induced PAH in EC ET B –/– mice may be due to 
an increase in the tone of resistance arterioles smaller 
than those possible to study in myography experiments.
 Several studies in mice report weight loss following 
exposure to hypoxia, an effect that is incompletely under-
stood but may involve altered expression of genes regu-
lated by hypoxia-inducible factor    [46] . However, we saw 
no difference in weight loss (approx. 3.4 g) between con-
trols and EC ET B –/– mice. Although weight loss contrib-
uted to the increase in RV/BW ratio in both groups, we 
only observed an absolute increase in RV mass [as deter-
mined by RV/(LV+S) ratio and RV/TV ratio] in EC
ET B –/– mice. This increase is, therefore, likely to reflect a 
true RV hypertrophic response to the increased PAP in 
EC ET B –/– mice, rather than any disproportionate weight 
loss in KOs.
 In conclusion, this study indicates that EC ET B play an 
important protective role during prolonged hypoxia that 
limits vascular remodelling and the development of pul-
monary hypertension.
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